Financial Performance - Revenue for the first quarter of 2025 reached CNY 75.51 million, representing an increase of 8.66% year-over-year[8] - Net profit attributable to shareholders for the first quarter of 2025 was CNY 5.06 million, up 10.43% from the same period last year[8] - Total operating revenue for Q1 2025 reached ¥75,506,685.42, an increase from ¥69,487,663.50 in Q1 2024, representing an increase of approximately 8.8%[34] - Net profit for Q1 2025 was ¥5,061,062.76, compared to ¥4,583,048.38 in Q1 2024, indicating a growth of approximately 10.4%[35] - Operating revenue for Q1 2025 was 75,223,509.38, an increase of 7.1% compared to 70,228,052.11 in Q1 2024[37] - Net profit for Q1 2025 was 4,476,102.92, a decrease of 8.7% from 4,904,799.42 in Q1 2024[38] Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 4.87 million, a decline of 221.90% compared to the previous year[8] - Cash and cash equivalents were reported at ¥127,849,719.56 on March 31, 2025, compared to ¥575,999,418.33 at the end of 2024[28] - Cash flow from operating activities in Q1 2025 was negative at -4,871,716.85, compared to a positive 3,996,538.12 in Q1 2024[40] - Total cash and cash equivalents at the end of Q1 2025 were 121,529,943.27, a decrease from 255,745,860.34 at the end of Q1 2024[40] - The ending balance of cash and cash equivalents decreased to $89.76 million from $210.52 million, a decline of approximately 57.6% year-over-year[42] - The net decrease in cash and cash equivalents was $433.77 million, worsening from a decrease of $291.97 million year-over-year[42] Assets and Liabilities - Total assets as of March 31, 2025, were CNY 743.83 million, a decrease of 0.19% compared to the end of 2024[8] - The company's total liabilities to assets ratio decreased to 17.00% from 17.92% year-over-year[8] - Total current assets amounted to ¥619,294,888.19 as of March 31, 2025, showing a slight increase from ¥616,938,129.16 on December 31, 2024[28] - Total liabilities decreased to ¥126,482,125.28 as of March 31, 2025, from ¥133,535,318.35 at the end of 2024[30] - Total liabilities decreased to ¥115,255,499.51 from ¥121,766,784.25, showing a reduction of about 5.0%[33] - The company reported a significant decrease in cash and cash equivalents, down 77.80% to CNY 127.85 million[9] Shareholder Information - The total number of ordinary shareholders was 6,077 as of the end of the reporting period[15] - The largest shareholder, Changhong Meiling Co., Ltd., holds 45,900,000 shares, representing 47.45% of total shares[16] - Zhongke Xianxing (Beijing) Asset Management Co., Ltd. is the second largest shareholder with 19,500,000 shares, accounting for 20.16%[16] - The total shares held by the top ten shareholders amount to 71,353,416, which is 73.76% of the total shares[17] Legal and Compliance Matters - There is a pending lawsuit involving Zhejiang Teruisi Pharmaceutical Co., Ltd. with a claim amount of 5,603,675, which represents 0.91% of the company's net assets[21] - The company has provided guarantees totaling 40,000,000, with all guarantees being joint and several liabilities[23] - The company has a frozen cash asset of 5,603,675, which constitutes 0.75% of total assets due to the aforementioned lawsuit[24] - The company has timely disclosed all major events and compliance matters during the reporting period[20] Research and Development - Research and development expenses for Q1 2025 were ¥7,379,901.17, down from ¥8,316,034.09 in Q1 2024, indicating a decrease of about 11.3%[34] - Research and development expenses decreased to 6,760,647.45 in Q1 2025 from 7,823,662.81 in Q1 2024, a reduction of 13.5%[37] Other Financial Metrics - The weighted average return on equity based on net profit attributable to shareholders was 0.82%[8] - Basic and diluted earnings per share for Q1 2025 were both ¥0.0523, an increase from ¥0.0474 in Q1 2024[36] - The company reported a foreign exchange gain of ¥1,806,935.93 in Q1 2025, compared to a gain of ¥1,653,236.12 in Q1 2024[35] - The company’s deferred income decreased to ¥3,138,204.56 from ¥3,413,183.50, indicating a decline of approximately 8.0%[33]
中科美菱(835892) - 2025 Q1 - 季度财报